Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Teaser interview NeoDynamics Equity Research report

By Claus ThestrupCEO, Sweden
NeoDynamics

Read full report here:

https://content.inderes.se/assets/65332e2a-2e4a-444a-8e97-d5c162deecde

Key investment reasons:

NeoDynamic's ultrasound-guided biopsy technology NeoNavia® addresses an unmet need in the diagnosis of breast cancer, the most prevalent female cancer type. The breast cancer diagnostic market is expected to be a USD 1.7bn market worldwide by 2025.

Following an FDA approval of NeoNavia®, the primary value driver and focus for NeoDynamics is successful commercialization in the US market, where NeoDynamics is launching NeoNavia® with the FlexiPulse® during 2023.

As a needle ultrasound-guided biopsy, NeoNavia® competes in the premium segment of the breast biopsymarket, which allows NeoDynamics to price and compete based on clinical added benefits as opposed to cost competition.

Based on NeoDynamics’ expectations and assuming different levels of US market share and pricing etc.(see assumptions p. 8-9) our DCF-model indicates that the current market valuation of NeoDynamics implicitly reflects less than 10% of the value potential of a US launch in 2023 and a successful commercialization in the following years (medium market share scenario).

Recent videos

Talenom - Planned demerger and strategies of Talenom and Easor
18.12.2025, 11.00 Talenom
HCA Morgenbørs 18/12 - Vi ser ind i en flad europæiske åbning trods markante US fald, vi undgår igen tech-nedturen
18.12.2025, 09.55 ISS
Flügger - Q2 2025/26 Analytiker video
18.12.2025, 09.46 Flügger Group
Investing in the life science sector
18.12.2025, 07.47
HCA Morgenbørs 17/12 - Vi ser ind i lidt afventende markeder ovenpå en noget svag jobmarkedsrapport
17.12.2025, 09.21 Roblon
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.